Lysine lactylation (Kla) might be a novel therapeutic target for breast cancer

BMC Medical Genomics

Table 2 Drug susceptibility analysis according to CCR7

Drug	cor	pvalue	Drug	cor	pvalue
Nelarabine	0.9164	< 0.0001	Cytarabine	0.3359	0.0087
Fluphenazine	0.6381	< 0.0001	Melphalan	0.3317	0.0096
Dexamethasone Decadron	0.6148	< 0.0001	Decitabine	0.3291	0.0102
Chelerythrine	0.5764	< 0.0001	Thiotepa	0.3289	0.0103
PX-316	0.5061	< 0.0001	Digoxin	0.3234	0.0117
Asparaginase	0.4518	0.0003	Triethylenemelamine	0.3189	0.0130
Fludarabine	0.4292	0.0006	XK-469	0.3164	0.0138
Hydroxyurea	0.4201	0.0008	Etoposide	0.3140	0.0146
Cyclophosphamide	0.4063	0.0013	Seliciclib	-0.3042	0.0181
Pipobroman	0.3800	0.0027	Cladribine	0.2983	0.0206
Fenretinide	0.3724	0.0034	Calusterone	0.2963	0.0215
Chlorambucil	0.3641	0.0042	LMP-400	0.2791	0.0308
Dexrazoxane	0.3573	0.0051	Nitrogen mustard	0.2770	0.0321
Ifosfamide	0.3486	0.0063	Carmustine	0.2724	0.0353
Arsenic trioxide	0.3481	0.0064	LY-294,002	-0.2651	0.0407
Idarubicin	0.3423	0.0074	Teniposide	0.2647	0.0409
Batracylin	0.3401	0.0079	Raltitrexed	0.2594	0.0453
Uracil mustard	0.3365	0.0086

ISSN: 1755-8794